HLA Typing for Transplant Market By Product and Services (Reagents and Consumables, Instruments, and Software and Services), Transplant Type (Solid Organ Transplant, Hematopoietic Stem Cell Transplant, and Others), Technology (Molecular Assay Technologies and Non- Molecular Assay Technologies), Application (Diagnostic Applications, and Research Applications), End-User, and Region - Trends, Analysis, and Forecast to 2035

• Till 2035, the HLA typing for transplant market size is expected to grow at a valuation of USD 1877 Million.
• The market was valued at USD 887 Million in 2024.
• At a CAGR of 8.0%, the market is projected to grow during the forecast period.

In order to match a suitable organ or stem cell donor for a transplant, HLA typing is a blood test that determines a person's unique Human Leukocyte Antigens (HLA) profile. The closer the donor and recipient match, the higher the probability of a successful transplant with a low risk of rejection; in other words, it's a method of assessing tissue compatibility prior to a transplant procedure.

The rising demand for organ transplants due to a rise in chronic diseases such as kidney failure and blood disorders, growing awareness for organ donation, and technological advancements lead to the HLA typing for transplant market growth. In addition to this, HLA typing for transplant reduces rejection rate, improves graft survival, and lowers the risk of complications this factors are leading to further expansion of the market.

Impact of AI on the Market:

Artificial Intelligence (AI) has a significant impact on HLA typing for transplant market. It improves donor-recipient matching accuracy and efficiency, allows for better patient outcomes by identifying optimal matches with a lower risk of rejection, recognizes patterns in complex HLA profiles, and efficiently and quickly analyzes large datasets to create more individualized matching strategies for each patient.

Key Drivers of Target Market:

HLA Typing for Transplant Reduces the Organ Rejection Rate which is Expected to Drive Market Growth

HLA typing, is an essential test performed before organ transplantation to check the compatibility between a donor and a recipient. A close HLA match significantly reduces the risk of organ rejection by reducing the immune response against the transplanted tissue, thereby leading to a minimized rejection rate.

• For instance, in June 2024, British Columbia became the first jurisdiction in the world to test an innovative method of matching donor organs to recipients. The aim of this project was to prevent organ rejection and reduce the need for patients to take harmful immune-suppressing drugs. HLA is a crucial protein which the body uses to distinguish from the foreign entities. Here HLA is used to test if the organ of the donor and recipient matches to prevent organ rejection.

Restraints:

Possible Errors in Interpretation of Data Obstructs the Market Growth

HLA typing involves intricate molecular analysis with a large number of possible HLA alleles, and this can lead to potential errors in interpretation, especially when using older testing methods. Since the immune system is less similarly to attack an organ that is closely matched, precise HLA matching is crucial for reducing the probability of organ rejection following a transplant. Therefore, when there is an error in interpreting it results in incompatible donor recipient match and results in the failure of the transplant.

• Counterbalance Statements: Double checking results, using high-resolution typing method, and implementing strict quality control measures within the laboratory while performing the HLA typing are a few possible resolutions of this issue.

Opportunities:

Future Advancements in HLA Typing for Transplant will Create Significant Opportunities

It is anticipated that additional advanced technological developments in HLA typing would enable more accurate matching, better detection of possible issues, and perhaps larger donor pools through enhanced compatibility evaluations. Some of the future advancements include assessment using next-generation sequencing (NGS), HLA haplotype analysis, antibody screening, and personalized medicine.

• For instance, in October 2024, CareDx, Inc., a leading precision medicine company, announced a strategic partnership to drive the next wave of innovation in HLA genotyping for organ and stem cell transplant matching. Due to this strategic partnership HLA labs were able to participate in an Early Access Program using CareDx’s NGS-based AlloSeq Tx 17 HLA typing solution incorporating Dovetail Genomics cutting-edge Hi-C LinkPrep technology. This helped to achieve high-resolution genotyping and haplotyping without the need for family genotyping studies.

The market is classified into product, transplant type, technology, application, end user, and region.

Product

According to product type, the market is branched into reagents and consumables, instruments, and software and services. The reagents and consumables segment held the highest HLA typing for transplant market share as it has a widespread application in diagnostic laboratories and transplant centers.

• For instance, in September 2021, Thermo Fisher Scientific announced two new additions to its transplant diagnostics portfolio. These new products would enable transplant laboratories to better characterize samples and bring speed and confidence to the transplant laboratory. One of the products launched by the company was a new serum treatment reagent which was designed to address nonspecific antibody reactivity in some samples.

Transplant Type

Based on transplant type, the market is sub-segmented into solid organ transplant, hematopoietic stem cell transplant, and others. The hematopoietic stem cell transplant (HSCT) segment is attributed to dominate the market as HLA typing is in higher demand than solid organ transplants, due to its use in treating hematological disorders. Additionally, HLA typing is important for selecting donors for HSCT as it helps in reducing transplant-related mortality.

• For instance, in March 2024, according to an article published by Karger AG, HLA typing serves as a standard practice in hematopoietic stem cell transplantation to ensure compatibility between donors and recipients, preventing the occurrence of allograft rejection and graft-versus-host disease. The adoption of third-generation sequencing technologies, such as Oxford Nanopore (ONT) sequencing and single-molecule real-time (SMRT) sequencing, can revolutionize the field by offering improved accuracy, reduced ambiguity, and enhanced assessment of compatibility in HSCT.

Technology

On the premise of technology, the market is bifurcated into molecular assay technologies and non-molecular assay technologies. Molecular techniques are more accurate and fast as compared to the traditional serology technology, thereby molecular assay technologies segment takes control over the market.

• For instance, in October 2023, GenDx, a Eurobio Scientific Company, announced the launch of its newly developed product, NGS-Turbo, designed for HLA typing using Oxford Nanopore Technologies sequencing devices, which was a molecular assay technology. NGS-Turbo represented a significant leap forward in the field of HLA typing, and offered unparalleled speed and efficiency when time was of the essence.

Application

By application, the market is pigeonholed into diagnostic applications and research applications. The diagnostic applications segment is predicted to rule the market as the use of HLA typing is increasing in diagnosing chronic and uncommon disorders, such as CKD and thalassemia. Additionally, HLA typing is also used in preimplantation genetic diagnosis.

• For instance, in March 2022, Immucor, Inc., a global leader in transfusion and transplantation diagnostics announced two additions to its transplant diagnostics portfolio, this demonstrated its ongoing commitment to new advancements in the field of histocompatibility. The launch was of MIA FORA NGS EXPRESS HLA Typing Software. This new software offered users of MIA FORA NGS MFlex HLA Typing assays, a faster and easier NGS analysis experience.

End-User

The market was categorized into independent reference laboratories, hospitals and transplant centers, research laboratories and academic institutes, and others. The hospitals and transplant centers segment is expected to have the most dominating market due to the increasing demand for organ transplants and advancements in hospital technology.

• For instance, in April 2023, Metropolis Healthcare Limited, launched the "NextGen HLA" Typing Test which was powered by the complex molecular technology Next Generation Sequencing (NGS). This was a high-resolution molecular test, which was performed for Hematopoietic Stem Cell Transplant (HSCT) & Solid organ transplantation. This test aided in the identification of a suitable donor for bone marrow, cord blood, or organ transplant by analyzing the Human Leukocyte Antigen (HLA) genes that a person had inherited from the parent.

Region

Geographically, the market is catalogued into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America: This region has largest HLA typing for transplant market share due to a number of factors. This includes high demand for transplants, advanced diagnostic technologies, established healthcare infrastructure, favorable reimbursement policies, and strong presence of key manufacturers.

• For instance, in October 2024, CareDx, Inc., a leading precision medicine company, announced new data and product enhancements. One of the latest launched product included AlloSeq NGS-based HLA typing solutions which were being featured demonstrating its clinical utility in living organ donation typing and bone marrow transplantation. The other product launched by CareDx was its newly improved QTYPE solution which included single bead antigen resolution to facilitate virtual crossmatching in deceased donor typing for faster transplant decisions.

Europe: This region has fastest growing market during the forecast period in comparison to the other regions. This is due to the region’s well-developed healthcare infrastructure, high adoption of advanced diagnostic technologies, a substantial patient base, and a strong regulatory environment.

• For instance, in November 2023, GenDx, a Eurobio Scientific Company, announced that the Company had entered into a collaboration with OSE Immunotherapeutics, which is a French biotech company dedicated to developing first-in-class assets in immuno-oncology, to develop and validate a companion diagnostic (CDx) test for high resolution HLA typing based on its IVDR registered NGSgo kit and NGSengine software. This test would support the confirmatory pivotal Phase 3 clinical trial of Tedopi cancer vaccine in preparation in Non-Small Cell Lung Cancer (NSCLC) second line treatment.

HLA Typing for Transplant Market Report Scope:

Attribute	Details
Market Size 2025	USD 929.9 Million
Projected Market Size 2035	USD 1877 Million
CAGR Growth Rate	8.0% (2025-2035)
Base year for estimation	2024
Forecast period	2025 – 2035
Market representation	Revenue in USD Million & CAGR from 2025 to 2035
Regional scope	North America - U.S. and Canada Europe – U.K., France, Russia, Italy, Spain, Netherlands,  and Rest of Europe Asia Pacific – China, India, Japan, Australia, Indonesia Malaysia, South Korea, and Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, and Rest of Latin America Middle East & Africa – GCC, Israel, South Africa, and Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segmentation:

By Product:

• Reagents and Consumables
  • Test Kits
  • Probes
  • Solutions
• Instruments
  • Molecular-Based Instruments
  • Sequence-Based Instruments
• Software and Services
  • Data Analysis
  • Interpretation
  • Others

By Transplant Type:

• Solid Organ Transplant
• Hematopoietic Stem Cell Transplant
• Others

By Technology

• Molecular Assay Technologies
• Non-Molecular Assay Technologies

By Application:

• Diagnostic Applications
• Research Applications

By End User:

• Independent Research Laboratories
• Hospitals and Transplant Centers
• Laboratories and Academic Institutes
• Others

By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Russia
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • Indonesia
  • Malaysia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating in this sector are adopting strategies, such as collaborations, global reach, donor registry integration, and technological advancements. The companies operating in this market are Thermo Fisher Scientific Inc., Illumina, Inc., Immucor, CareDx, Inc., Bio-Rad Laboratories, Inc., and others.

HLA Typing for Transplant Market Companies:

• Thermo Fisher Scientific Inc.
• Illumina, Inc.
• Immucor
• CareDx, Inc.
• Bio-Rad Laboratories, Inc.
• DiaSorin S.p.A.
• GenDx
• QIAGEN
• Hologic, Inc.
• F. Hoffmann-La Roche Ltd
• Biofortuna Limited
• EKF Diagnostics Holdings plc.
• BD
• Fujirebio

View a Additional List of Companies in HLA Typing for Transplant Market

• In August 2024, the FDA had granted 501(k) clearance to the SeCore CDx HLA a Sequencing System for use as a companion diagnostic for afamitresgene autoleucel among patients with previously treated advanced synovial sarcoma. This companion diagnostic is designed to employ a sequence-based typing method to screen for HLA-A alleles in genomic DNA purified from whole blood specimens.
• In May 2024, the Christian Medical College (CMC), Vellore announced that for financially disadvantaged patients in the specified age group who require a Haematopoietic Stem Cell Transplantation, the government (CIL-CSR) and CMC supportive funds would cover the majority of the transplant expenses, including HLA typing, accommodation, and food.

Analyst View:

The HLA typing for transplants market is expanding as a result of increased awareness of organ donation, the need for organ transplants due to an increase in chronic illnesses such renal failure and blood disorders, and technical developments. Furthermore, HLA typing for transplants lowers the risk of complications, increases graft survival, and decreases the rejection rate, all of which contribute to the market's continued growth.

More Related Reports

Genotyping Market
Genotyping Assay Market
Chromatography Instruments Market
Digital Writing Instruments Market
Gynecology Surgical Instruments Market

Company Name	Thermo Fisher Scientific Inc.
Headquarter	Massachusetts, United States
CEO	Mr. Marc N. Casper
Employee Count (2024)	122,000 Employees